
Dr. McGregor on the Need to Develop Novel Targets in RCC
Bradley McGregor, MD, discusses the need to develop novel, actionable targets in renal cell carcinoma.
Bradley McGregor, MD, clinical director, Lank Center for Genitourinary Oncology, senior physician, Dana-Farber Cancer Institute, and instructor of medicine, Harvard Medical School, discusses the need to develop novel, actionable targets in renal cell carcinoma (RCC).
Although the treatment landscape of RCC features effective combination regimens, some patients still experience disease progression, explains McGregor.
At the
Moreover, a phase 3 study (NCT04195750) is evaluating MK-6482 versus everolimus (Afinitor) in patients with advanced RCC, concludes McGregor.



































